Clinical Trials Logo

NUT Midline Carcinoma (NMC) clinical trials

View clinical trials related to NUT Midline Carcinoma (NMC).

Filter by:
  • None
  • Page 1

NCT ID: NCT02698176 Terminated - Clinical trials for Non-small Cell Lung Cancer (NSCLC)

A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-8628-006)

Start date: May 4, 2016
Phase: Phase 1
Study type: Interventional

This is a study to determine the recommended dose of birabresib (MK-8628)(formerly known as OTX015) for further studies in participants with advanced nuclear protein in testis (NUT) midline carcinoma (NMC), triple negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), or castration-resistant prostate cancer (CRPC). This is a two-part parallel study: Part A will establish the recommended dose by evaluating dose limiting toxicity (DLT), safety, discontinuation, and early efficacy and Part B will enroll participants with NMC only and will evaluate safety and efficacy in this population.